冠脉计算机断层扫描血管成像筛查对无症状中国人群血脂管理和危险因素控制的作用:一项基于社区的平行组开放标签随机临床试验(RESPECT2)
RESPECT2试验拟招募约3400名中年无症状社区参与者,按1:1随机分为传统心血管风险评分指导组和CCTA指导组。主要结局为6个月和12个月时规律服用降脂药物的比例。该研究是首个在无症状社区人群中比较CCTA指导与传统风险评分指导的一级预防策略的随机临床试验。
要点
- CCTA指导组血脂管理依据CCTA结果个体化,传统组依据传统风险水平。
- 两组血压、血糖目标及生活方式建议相同。
- 主要结局为6个月和12个月时规律服用降脂药物的比例。
核心结论
- 该研究是首个在无症状社区人群中检验CCTA指导与传统风险评分指导的一级预防策略有效性的随机临床试验。
研究设计与样本
- 基于社区的平行组开放标签随机临床试验,拟招募约3400名中年无症状社区参与者,按1:1随机分为传统心血管风险评分指导组(常规护理组)或CCTA指导组。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 主要结局为6个月和12个月时规律服用降脂药物的参与者比例。
- 次要结局包括12个月时达到低密度脂蛋白胆固醇降低目标的参与者比例、从基线至12个月血脂水平的平均变化、依从性障碍、与CCTA检查相关的不良反应以及心血管事件。
- 排除标准包括患有心血管疾病、既往接受降脂治疗、存在CCTA禁忌证或患有影响寿命的严重疾病。
- 干预策略包括血压、血糖和血脂管理以及生活方式调整;两组血压和血糖目标及生活方式调整建议相同,血脂管理分别基于传统风险水平或CCTA结果个体化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipid management based on cardiovascular risk level is the cornerstone of primary prevention of coronary artery disease (CAD), while the accuracy and adherence of traditional cardiovascular risk stratification have been questioned. Prevention strategies based on imaging screening for atherosclerotic plaques are found to be more objective and adherent in recent studies. This trial aims to investigate the role of coronary computed tomography angiography (CCTA) in guiding the primary prevention of CAD in a randomized controlled design. METHODS: Approximately 3400 middle-aged asymptomatic community participants will be recruited and randomized in a 1:1 ratio to a traditional cardiovascular risk score-guided (usual care group) or CCTA-guided (CCTA group) strategy. Participants with cardiovascular disease, prior lipid-lowering therapy, CCTA contraindication, or serious diseases that affect life span will be excluded. The intervention strategy includes blood pressure, blood glucose, and lipid management and lifestyle modifications. Blood pressure and glucose targets and lifestyle modification recommendations keep the same in both strategies, while lipid management is personalized based on traditional risk level or CCTA results, respectively. The primary outcome is the proportion of participants taking lipid-lowering medication regularly at both 6 and 12 months. The secondary outcomes include the proportion of participants achieving low-density lipoprotein cholesterol lowering targets at 12 months, mean changes in lipid levels from baseline to 12 months, barriers to adherence, adverse reactions related to CCTA examination, and cardiovascular events. DISCUSSION: The study is the first randomized clinical trial to examine the effectiveness of a CCTA-guided versus a traditional risk score-guided primary prevention strategy in an asymptomatic community-based population. TRIAL REGISTRATION: ClinicalTrials.gov NCT05725096. Registered on 2 February 2023.
引用
- Guo X, Li J, Zhu Y, et al. Role of the screening with coronary computed tomography angiography on lipid management and risk factors control in an asymptomatic Chinese population: a community-based, parallel-group, open-label, randomized clinical trial (RESPECT2). Trials. 2024. PMID: 39350195. doi:10.1186/s13063-024-08469-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。